17 results on '"Shi, Zhumei"'
Search Results
2. Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas
- Author
-
Yin, Jianxing, Wang, Xiefeng, Ge, Xin, Ding, Fangshu, Shi, Zhumei, Ge, Zehe, Huang, Guang, Zhao, Ningwei, Chen, Dongyin, Zhang, Junxia, Agnihotri, Sameer, Cao, Yuandong, Ji, Jing, Lin, Fan, Wang, Qianghu, Zhou, Qigang, Wang, Xiuxing, You, Yongping, Lu, Zhimin, and Qian, Xu
- Published
- 2023
- Full Text
- View/download PDF
3. Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation
- Author
-
Ge, Zehe, Xu, Miao, Ge, Yuqian, Huang, Guang, Chen, Dongyin, Ye, Xiuquan, Xiao, Yibei, Zhu, Hongyu, Yin, Rong, Shen, Hua, Ma, Gaoxiang, Qi, Lianwen, Wei, Guining, Li, Dongmei, Wei, Shaofeng, Zhu, Meng, Ma, Hongxia, Shi, Zhumei, Wang, Xiuxing, Ge, Xin, and Qian, Xu
- Published
- 2023
- Full Text
- View/download PDF
4. METTL3-mediated m6A modification of LINC00839 maintains glioma stem cells and radiation resistance by activating Wnt/β-catenin signaling
- Author
-
Yin, Jianxing, Ding, Fangshu, Cheng, Zhangchun, Ge, Xin, Li, Yanhui, Zeng, Ailiang, Zhang, Junxia, Yan, Wei, Shi, Zhumei, Qian, Xu, You, Yongping, Ding, Zhiliang, Ji, Jing, and Wang, Xiefeng
- Published
- 2023
- Full Text
- View/download PDF
5. Reactivating PTEN to impair glioma stem cells by inhibiting cytosolic iron-sulfur assembly.
- Author
-
Yin, Jianxing, Ge, Xin, Ding, Fangshu, He, Liuguijie, Song, Keying, Shi, Zhumei, Ge, Zehe, Zhang, Junxia, Ji, Jing, Wang, Xiefeng, Zhao, Ningwei, Shu, Chuanjun, Lin, Fan, Wang, Qianghu, Zhou, Qigang, Cao, Yuandong, Liu, Wentao, Ye, Dan, Rich, Jeremy N., and Wang, Xiuxing
- Subjects
GLIOMAS ,STEM cells ,METHYLGUANINE ,BRAIN tumors ,DRUGS ,GLIOBLASTOMA multiforme - Abstract
Glioblastoma, the most lethal primary brain tumor, harbors glioma stem cells (GSCs) that not only initiate and maintain malignant phenotypes but also enhance therapeutic resistance. Although frequently mutated in glioblastomas, the function and regulation of PTEN in PTEN-intact GSCs are unknown. Here, we found that PTEN directly interacted with MMS19 and competitively disrupted MMS19-based cytosolic iron-sulfur (Fe-S) cluster assembly (CIA) machinery in differentiated glioma cells. PTEN was specifically succinated at cysteine (C) 211 in GSCs compared with matched differentiated glioma cells. Isotope tracing coupled with mass spectrometry analysis confirmed that fumarate, generated by adenylosuccinate lyase (ADSL) in the de novo purine synthesis pathway that is highly activated in GSCs, promoted PTEN C211 succination. This modification abrogated the interaction between PTEN and MMS19, reactivating the CIA machinery pathway in GSCs. Functionally, inhibiting PTEN C211 succination by reexpressing a PTEN C211S mutant, depleting ADSL by shRNAs, or consuming fumarate by the US Food and Drug Administration–approved prescription drug N-acetylcysteine (NAC) impaired GSC maintenance. Reexpressing PTEN C211S or treating with NAC sensitized GSC-derived brain tumors to temozolomide and irradiation, the standard-of-care treatments for patients with glioblastoma, by slowing CIA machinery–mediated DNA damage repair. These findings reveal an immediately practicable strategy to target GSCs to treat glioblastoma by combination therapy with repurposed NAC. Editor's summary: Glioma stem cells promote glioblastoma growth and therapy resistance but are hard to target. Yin et al. report that posttranslational succination of PTEN at residue 211 (cysteine) promotes glioma stem cell maintenance by reactivating cytosolic iron-sulfur cluster assembly formation. This PTEN succination was driven by purine biosynthesis–derived fumarate. Administration of N-acetylcysteine to deplete the fumarate sensitized xenografted tumors in mice to both standard-of-care temozolomide and irradiation, indicating potential translational relevance for this difficult-to-treat cancer. —Catherine Charneski [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Sterol regulatory element-binding protein 2 maintains glioblastoma stem cells by keeping the balance between cholesterol biosynthesis and uptake.
- Author
-
Gu, Danling, Zhou, Fengqi, You, Hao, Gao, Jiancheng, Kang, Tao, Dixit, Deobrat, Wu, Qiulian, Yang, Kailin, Ci, Shusheng, Shan, Danyang, Fan, Xiao, Yuan, Wei, Zhang, Qian, Lu, Chenfei, Li, Daqi, Zhao, Ningwei, Shi, Zhumei, Gao, Wei, Lin, Fan, and Man, Jianghong
- Published
- 2023
- Full Text
- View/download PDF
7. Chromium (VI)‐induced ALDH1A1/EGF axis promotes lung cancer progression.
- Author
-
Ge, Xin, Li, Mengdie, Song, Guo‐Xin, Zhang, Zhixiang, Yin, Jianxing, Ge, Zehe, Shi, Zhumei, Liu, Ling‐Zhi, Jiang, Bing‐Hua, Qian, Xu, and Shen, Hua
- Subjects
LUNG cancer ,CANCER invasiveness ,ALDEHYDE dehydrogenase ,CANCER cell growth ,CHROMIUM - Abstract
Cr(VI) is broadly applied in industry. Cr(VI) exposure places a big burden on public health, thereby increasing the risk of lung squamous cell carcinoma (LUSC). The mechanisms underlying Cr(VI)‐induced LUSC remain largely elusive. Here, we report that the cancer stem cell (CSC)/tumour‐initiating cell (TIC)‐like subgroup within Cr(VI)‐transformed bronchial epithelial cells (CrT) promotes lung cancer tumourigenesis. Mechanistically, Cr(VI) exposure specifically increases the expression levels of aldehyde dehydrogenase 1A1 (ALDH1A1), a CSC marker, through KLF4‐mediated transcription. ALDH1A1 maintains self‐renewal of CrT/TICs and facilitates the expression and secretion of EGF from CrT/TICs, which subsequently promotes the activation of EGFR signalling in differentiated cancer cells and tumour growth of LUSC. In addition, the ALDH1A1 inhibitor A37 and gemcitabine synergistically suppress LUSC progression. Importantly, high ALDH1A1 expression levels are positively correlated with advanced clinical stages and predict poor survival in LUSC patients. These findings elucidate how ALDH1A1 modulates EGF secretion from TICs to facilitate LUSC tumourigenesis, highlighting new therapeutic strategies for malignant lung cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. HDAC2- and EZH2-Mediated Histone Modifications Induce PDK1 Expression through miR-148a Downregulation in Breast Cancer Progression and Adriamycin Resistance.
- Author
-
Xie, Yunxia, Shi, Zhumei, Qian, Yingchen, Jiang, Chengfei, Liu, Wenjing, Liu, Bingjie, and Jiang, Binghua
- Subjects
- *
DISEASE progression , *REVERSE transcriptase polymerase chain reaction , *DOXORUBICIN , *WESTERN immunoblotting , *IMMUNOHISTOCHEMISTRY , *PRECIPITIN tests , *PEARSON correlation (Statistics) , *T-test (Statistics) , *EPITHELIAL-mesenchymal transition , *FLUORESCENT antibody technique , *DESCRIPTIVE statistics , *STATISTICAL hypothesis testing , *CELL lines , *TUMOR markers , *DATA analysis software , *EPIGENOMICS , *BREAST tumors , *DRUG resistance in cancer cells - Abstract
Simple Summary: Epigenetic modification plays an important regulatory role in breast cancer progression. However, the relationship between epigenetic modification with tumor metabolism has not yet been fully elucidated. PDK1, as a key enzyme in glucose metabolism, mediates multiple tumors development. But, the mechanism of epigenetic modification in regulating PDK1 remains unclear in breast cancer. Here, we demonstrated that HDAC2 and EZH2 upregulated PDK1 expression through inhibiting miR-148a. Importantly, miR-148a targeting PDK1 regulated breast cancer cells glycolysis, invasion, epithelial-mesenchymal transition (EMT) and Adriamycin resistance. Our results suggested that the HDAC2/EZH2/miR-148a/PDK1 axis may be a promising potential therapeutic strategy. Background: Breast cancer has one of highest morbidity and mortality rates for women. Abnormalities regarding epigenetics modification and pyruvate dehydrogenase kinase 1 (PDK1)-induced unusual metabolism contribute to breast cancer progression and chemotherapy resistance. However, the role and mechanism of epigenetic change in regulating PDK1 in breast cancer remains to be elucidated. Methods: Gene set enrichment analysis (GSEA) and Pearson's correlation analysis were performed to analyze the relationship between histone deacetylase 2 (HDAC2), enhancer of zeste homologue 2 (EZH2), and PDK1 in database and human breast cancer tissues. Dual luciferase reporters were used to test the regulation between PDK1 and miR-148a. HDAC2 and EZH2 were found to regulate miR-148a expression through Western blotting assays, qRT-PCR and co-immunoprecipitation assays. The effects of PDK1 and miR-148a in breast cancer were investigated by immunofluorescence (IF) assay, Transwell assay and flow cytometry assay. The roles of miR-148a/PDK1 in tumor growth were investigated in vivo. Results: We found that PDK1 expression was upregulated by epigenetic alterations mediated by HDAC2 and EZH2. At the post-transcriptional level, PDK1 was a new direct target of miR-148a and was upregulated in breast cancer cells due to miR-148a suppression. PDK1 overexpression partly reversed the biological function of miR-148a—including miR-148a's ability to increase cell sensitivity to Adriamycin (ADR) treatment—inhibiting cell glycolysis, invasion and epithelial–mesenchymal transition (EMT), and inducing apoptosis and repressing tumor growth. Furthermore, we identified a novel mechanism: DNMT1 directly bound to EZH2 and recruited EZH2 and HDAC2 complexes to the promoter region of miR-148a, leading to miR-148a downregulation. In breast cancer tissues, HDAC2 and EZH2 protein expression levels also were inversely correlated with levels of miR-148a expression. Conclusion: Our study found a new regulatory mechanism in which EZH2 and HDAC2 mediate PDK1 upregulation by silencing miR-148a expression to regulate cancer development and Adriamycin resistance. These new findings suggest that the HDAC2/EZH2/miR-148a/PDK1 axis is a novel mechanism for regulating cancer development and is a potentially promising target for therapeutic options in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas.
- Author
-
Shi, Zhumei, Ge, Xin, Li, Mengdie, Yin, Jianxing, Wang, Xiefeng, Zhang, Junxia, Chen, Dongyin, Li, Xinjian, Wang, Xiuxing, Ji, Jing, You, Yongping, and Qian, Xu
- Subjects
- *
METHYLGUANINE - Published
- 2022
- Full Text
- View/download PDF
10. Diallyl trisulfide sensitizes radiation therapy on glioblastoma through directly targeting thioredoxin 1.
- Author
-
Tian, Yangyang, Ge, Zehe, Xu, Miao, Ge, Xin, Zhao, Mengjie, Ding, Fangshu, Yin, Jianxing, Wang, Xiuxing, You, Yongping, Shi, Zhumei, and Qian, Xu
- Subjects
- *
THIOREDOXIN , *MICHAEL reaction , *METHYLGUANINE , *GLIOBLASTOMA multiforme , *RADIOTHERAPY , *REACTIVE oxygen species - Abstract
Radiotherapy is a standard-of-care treatment approach for glioblastoma (GBM) patients, but therapeutic resistance to radiotherapy remains a major challenge. Here we demonstrate that diallyl trisulfide (DATS) directly conjugates with cysteine (C) 32 and C35 (C32/35) residues of thioredoxin 1 (Trx1) through Michael addition reactions. Due to localizing in activity center of Trx1, the conjugation between DATS and C32/35 results in inhibition of Trx1 activity, therefore disturbing thioredoxin system and leading to accumulated levels of reactive oxygen species (ROS). High levels of Trx1 expression are correlated with poor prognosis of glioma patients. Notably, we reveal that DATS synergistically enhances irradiation (IR)-induced ROS accumulation, apoptosis, DNA damage, as well as inhibition of tumor growth of GBM cells. These findings highlight the potential benefits of DATS in sensitizing radiotherapy of GBM patients. [Display omitted] • Thioredoxin 1 (Trx1) was identified as the direct target of Diallyl trisulfide (DATS). • DATS conjugates with C32/35 residues of Trx1 through Michael addition reactions. • The conjugation of DATS with Trx1 inhibited Trx1 activity and disturbed redox balance. • DATS synergistically enhanced the radiotherapy effects of GBM cells. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma.
- Author
-
Ge, Xin, Li, Mengdie, Yin, Jianxing, Shi, Zhumei, Fu, Yao, Zhao, Ningwei, Chen, Hongshan, Meng, Longxiyu, Li, Xinjian, Hu, Zhibin, Zhao, Xiaozhi, Guo, Hongqian, and Qian, Xu
- Subjects
- *
RENAL cell carcinoma , *PI3K/AKT pathway , *NEOPLASTIC cell transformation , *SUNITINIB , *POST-translational modification - Abstract
Fumarate is an oncometabolite. However, the mechanism underlying fumarate-exerted tumorigenesis remains unclear. Here, utilizing human type2 papillary renal cell carcinoma (PRCC2) as a model, we show that fumarate accumulates in cells deficient in fumarate hydratase (FH) and inhibits PTEN to activate PI3K/AKT signaling. Mechanistically, fumarate directly reacts with PTEN at cysteine 211 (C211) to form S-(2-succino)-cysteine. Succinated C211 occludes tethering of PTEN with the cellular membrane, thereby diminishing its inhibitory effect on the PI3K/AKT pathway. Functionally, re-expressing wild-type FH or PTEN C211S phenocopies an AKT inhibitor in suppressing tumor growth and sensitizing PRCC2 to sunitinib. Analysis of clinical specimens indicates that PTEN C211 succination levels are positively correlated with AKT activation in PRCC2. Collectively, these findings elucidate a non-metabolic, oncogenic role of fumarate in PRCC2 via direct post-translational modification of PTEN and further reveal potential stratification strategies for patients with FH loss by combinatorial AKTi and sunitinib therapy. [Display omitted] • Fumarate directly targets and succinates PTEN at C211 • C211 succination abrogates the interaction of PTEN with the cellular membrane • PTEN C211 succination is positively correlated with PI3K/AKT activation in PRCC2 • Inhibiting PTEN C211 succination or AKT sensitizes PRCC2 to sunitinib treatment Ge et al. report that fumarate, an oncometabolite, succinates PTEN at C211, which abrogates the binding of PTEN with the cellular membrane. C211 succination of PTEN thereby activates PI3K/AKT signaling and promotes tumor growth of PRCC2. Inhibiting PTEN C211 succination or AKT activation enhances sensitivity of PRCC2 to sunitinib treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells.
- Author
-
Li M, Zhang Z, He L, Wang X, Yin J, Wang X, You Y, Qian X, Ge X, and Shi Z
- Abstract
Background: The high fatality rate of glioblastoma (GBM) is attributed to glioblastoma stem cells (GSCs), which exhibit heterogeneity and therapeutic resistance. Metabolic plasticity of mitochondria is the hallmark of GSCs. Targeting mitochondrial biogenesis of GSCs is crucial for improving clinical prognosis in GBM patients., Methods: SMYD2-induced PGC1α methylation and followed nuclear export is confirmed by co-immunoprecipitation, cellular fractionation, and immunofluorescence. The effects of SMYD2/PGC1α/CRM1 axis on GSCs mitochondrial biogenesis is validated by OCR, ECAR and intracranial glioma model., Results: PGC1α methylation causes disabled mitochondrial function to maintain the stemness, thereby enhancing radio-resistance of GSCs. SMYD2 drives PGC1α K224 methylation (K224me), which is essential for promoting the stem-like characteristics of GSCs. PGC1α K224me is preferred binding with CRM1, accelerating PGC1α nuclear export and subsequent dysfunction. Targeting PGC1α methylation exhibits significant radiotherapeutic efficacy and prolongs patient survival., Conclusions: These findings unveil a novel regulatory pathway involving mitochondria that governs stemness in GSCs, thereby emphasizing promising therapeutic strategies targeting PGC1α and mitochondria for the treatment of GBM., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
13. HSP90B1-mediated plasma membrane localization of GLUT1 promotes radioresistance of glioblastomas.
- Author
-
Li Y, Ge Y, Zhao M, Ding F, Wang X, Shi Z, Ge X, Wang X, and Qian X
- Abstract
Ionizing radiation is a popular and effective treatment option for glioblastoma (GBM). However, resistance to radiation therapy inevitably occurs during treatment. It is urgent to investigate the mechanisms of radioresistance in GBM and to find ways to improve radiosensitivity. Here, we found that heat shock protein 90 beta family member 1 (HSP90B1) was significantly upregulated in radioresistant GBM cell lines. More importantly, HSP90B1 promoted the localization of glucose transporter type 1, a key rate-limiting factor of glycolysis, on the plasma membrane, which in turn enhanced glycolytic activity and subsequently tumor growth and radioresistance of GBM cells. These findings imply that targeting HSP90B1 may effectively improve the efficacy of radiotherapy for GBM patients, a potential new approach to the treatment of glioblastoma.
- Published
- 2023
- Full Text
- View/download PDF
14. Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages.
- Author
-
Yuan W, Zhang Q, Gu D, Lu C, Dixit D, Gimple RC, Gao Y, Gao J, Li D, Shan D, Hu L, Li L, Li Y, Ci S, You H, Yan L, Chen K, Zhao N, Xu C, Lan J, Liu D, Zhang J, Shi Z, Wu Q, Yang K, Zhao L, Qiu Z, Lv D, Gao W, Yang H, Lin F, Wang Q, Man J, Li C, Tao W, Agnihotri S, Qian X, Mack SC, Zhang N, You Y, Rich JN, Sun G, and Wang X
- Subjects
- Humans, Animals, Mice, Tumor-Associated Macrophages metabolism, Phosphatidylinositol 3-Kinases metabolism, Cell Line, Tumor, Neoplastic Stem Cells metabolism, Cell Proliferation, Tumor Microenvironment genetics, Glioblastoma pathology, Brain Neoplasms pathology
- Abstract
Purpose: The dynamic interplay between glioblastoma stem cells (GSC) and tumor-associated macrophages (TAM) sculpts the tumor immune microenvironment (TIME) and promotes malignant progression of glioblastoma (GBM). However, the mechanisms underlying this interaction are still incompletely understood. Here, we investigate the role of CXCL8 in the maintenance of the mesenchymal state of GSC populations and reprogramming the TIME to an immunosuppressive state., Experimental Design: We performed an integrative multi-omics analyses of RNA sequencing, GBM mRNA expression datasets, immune signatures, and epigenetic profiling to define the specific genes expressed in the mesenchymal GSC subsets. We then used patient-derived GSCs and a xenograft murine model to investigate the mechanisms of tumor-intrinsic and extrinsic factor to maintain the mesenchymal state of GSCs and induce TAM polarization., Results: We identified that CXCL8 was preferentially expressed and secreted by mesenchymal GSCs and activated PI3K/AKT and NF-κB signaling to maintain GSC proliferation, survival, and self-renewal through a cell-intrinsic mechanism. CXCL8 induced signaling through a CXCR2-JAK2/STAT3 axis in TAMs, which supported an M2-like TAM phenotype through a paracrine, cell-extrinsic pathway. Genetic- and small molecule-based inhibition of these dual complementary signaling cascades in GSCs and TAMs suppressed GBM tumor growth and prolonged survival of orthotopic xenograft-bearing mice., Conclusions: CXCL8 plays critical roles in maintaining the mesenchymal state of GSCs and M2-like TAM polarization in GBM, highlighting an interplay between cell-autonomous and cell-extrinsic mechanisms. Targeting CXCL8 and its downstream effectors may effectively improve GBM treatment., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
15. PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma.
- Author
-
Zhao M, Li Y, Lu C, Ding F, Xu M, Ge X, Li M, Wang Z, Yin J, Zhang J, Wang X, Ge Z, Xiao H, Xiao Y, Liu H, Liu W, Cao Y, Wang Q, You Y, Wang X, Yang K, Shi Z, and Qian X
- Subjects
- Humans, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha genetics, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha metabolism, Organelle Biogenesis, Mitochondria metabolism, Carrier Proteins metabolism, Transcription Factors genetics, Transcription Factors metabolism, Glioma genetics, Glioma radiotherapy, Glioma metabolism
- Abstract
Radiotherapy is a major component of standard-of-care treatment for gliomas, the most prevalent type of brain tumor. However, resistance to radiotherapy remains a major concern. Identification of mechanisms governing radioresistance in gliomas could reveal improved therapeutic strategies for treating patients. Here, we report that mitochondrial metabolic pathways are suppressed in radioresistant gliomas through integrated analyses of transcriptomic data from glioma specimens and cell lines. Decreased expression of peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α), the key regulator of mitochondrial biogenesis and metabolism, correlated with glioma recurrence and predicted poor prognosis and response to radiotherapy of patients with glioma. The subpopulation of glioma cells with low-mitochondrial-mass exhibited reduced expression of PGC1α and enhanced resistance to radiotherapy treatment. Mechanistically, PGC1α was phosphorylated at serine (S) 636 by DNA-dependent protein kinase in response to irradiation. Phosphorylation at S636 promoted the degradation of PGC1α by facilitating its binding to the E3 ligase RNF34. Restoring PGC1α activity with expression of PGC1α S636A, a phosphorylation-resistant mutant, or a small-molecule PGC1α activator ZLN005 increased radiosensitivity of resistant glioma cells by reactivating mitochondria-related reactive oxygen species production and inducing apoptotic effects both in vitro and in vivo. In summary, this study identified a self-protective mechanism in glioma cells in which radiotherapy-induced degradation of PGC1α and suppression of mitochondrial biogenesis play a central role. Targeted activation of PGC1α could help improve response to radiotherapy in patients with glioma., Significance: Glioma cells reduce mitochondrial biogenesis by promoting PGC1α degradation to promote resistance to radiotherapy, indicating potential therapeutic strategies to enhance radiosensitivity., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
16. β2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages.
- Author
-
Li D, Zhang Q, Li L, Chen K, Yang J, Dixit D, Gimple RC, Ci S, Lu C, Hu L, Gao J, Shan D, Li Y, Zhang J, Shi Z, Gu D, Yuan W, Wu Q, Yang K, Zhao L, Qiu Z, Lv D, Gao W, Yang H, Lin F, Wang Q, Man J, Li C, Tao W, Agnihotri S, Qian X, Shi Y, You Y, Zhang N, Rich JN, and Wang X
- Subjects
- Cell Line, Tumor, Ecosystem, Humans, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Stem Cells pathology, TOR Serine-Threonine Kinases, Transforming Growth Factor beta1, Tumor-Associated Macrophages, Brain Neoplasms metabolism, Brain Neoplasms pathology, Glioblastoma metabolism, Glioblastoma pathology, Tumor Microenvironment, beta 2-Microglobulin metabolism
- Abstract
Glioblastoma (GBM) is a complex ecosystem that includes a heterogeneous tumor population and the tumor-immune microenvironment (TIME), prominently containing tumor-associated macrophages (TAM) and microglia. Here, we demonstrated that β2-microglobulin (B2M), a subunit of the class I major histocompatibility complex (MHC-I), promotes the maintenance of stem-like neoplastic populations and reprograms the TIME to an anti-inflammatory, tumor-promoting state. B2M activated PI3K/AKT/mTOR signaling by interacting with PIP5K1A in GBM stem cells (GSC) and promoting MYC-induced secretion of transforming growth factor-β1 (TGFβ1). Inhibition of B2M attenuated GSC survival, self-renewal, and tumor growth. B2M-induced TGFβ1 secretion activated paracrine SMAD and PI3K/AKT signaling in TAMs and promoted an M2-like macrophage phenotype. These findings reveal tumor-promoting functions of B2M and suggest that targeting B2M or its downstream axis may provide an effective approach for treating GBM., Significance: β2-microglobulin signaling in glioblastoma cells activates a PI3K/AKT/MYC/TGFβ1 axis that maintains stem cells and induces M2-like macrophage polarization, highlighting potential therapeutic strategies for targeting tumor cells and the immunosuppressive microenvironment in glioblastoma., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
17. SP1-upregulated LBX2-AS1 promotes the progression of glioma by targeting the miR-491-5p/LIF axis.
- Author
-
Li W, Soufiany I, Lyu X, Lu C, Wei Y, Shi Z, and You Y
- Abstract
Background: Mounting evidences have shown the importance of lncRNAs in carcinogenesis and cancer progression. LBX2-AS1 is identified as an oncogenic lncRNA that is abnormally expressed in gastric cancer and lung cancer samples. This study aims to explore the potential role of LBX2-AS1 in regulating proliferation and EMT in glioma, and the underlying mechanism. Methods: Relative levels of LBX2-AS1 in glioma samples and cell lines were detected by qRT-PCR and FISH. In vivo and in vitro regulatory effects of LBX2-AS1 on proliferation and EMT were examined in the xenograft glioma model and glioma cells. The interaction between SP1 and LBX2-AS1 was assessed by ChIP. Through bioinformatic analyses, dual-luciferase reporter assay, RIP and Western blot, the regulation of LBX2-AS1 and miR-491-5p on the target gene LIF was identified. Results: LBX2-AS1 was upregulated in glioma samples and cell lines, and its transcription was promoted by binding to the transcription factor SP1. As a lncRNA mainly distributed in the cytoplasm, LBX2-AS1 sponge miR-491-5p to further upregulate LIF. The subsequent activated LIF/STAT3 signaling was responsible for promoting proliferation and EMT in glioma. Conclusion: LBX2-AS1 is upregulated by SP1 in glioma, which promotes the progression of glioma by targeting the miR-491-5p/LIF axis. In view of this, LBX2-AS1 is suggested as a novel diagnostic biomarker and therapeutic target of glioma., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.